ArticleThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2007
Patent ductus arteriosus: an overview.
Article in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 4 syntheses or guidelines pooled it, 184 citations in OpenAlex.
- Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants.The Cochrane database of systematic reviews · 2025Pooled it
- Prophylactic cyclo-oxygenase inhibitor drugs for the prevention of morbidity and mortality in preterm infants: a network meta-analysis.The Cochrane database of systematic reviews · 2022Pooled it
- Indomethacin for symptomatic patent ductus arteriosus in preterm infants.The Cochrane database of systematic reviews · 2021Pooled it
- Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants.The Cochrane database of systematic reviews · 2020Pooled it
- Trial
- Effect of chest shielding during phototherapy for hyperbilirubinemia on symptomatic patent ductus arteriosus - a double-blind randomized placebo-controlled trial.Pediatric research · 2024Trial
- Efficacy of pharmacologic closure of patent ductus arteriosus in small-for-gestational-age extremely preterm infants.Early human development · 2017Trial
- Selective early medical treatment of the patent ductus arteriosus in extremely low gestational age infants: a pilot randomised controlled trial (SMART-PDA).Archives of disease in childhood. Fetal and neonatal edition · 2026Article
- Select plasma oxylipins as potential biomarkers of effective indomethacin treatment response in preterm infants with patent ductus arteriosus.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Machine learning-based tool to assess risk of hemodynamically significant PDA in extremely premature infants.Pediatric research · 2026Article
- Article
- Clinical Impact of the PDA and Its Management on Outcomes of Preterm Infants with NEC: A Review.American journal of perinatology · 2026Review
- Management of type 2 endoleaks following endovascular thoracic aortic dissection repair associated with patent ductus arteriosus: A report of two cases in patients with Marfan syndrome.Journal of vascular surgery cases and innovative techniques · 2026Article
- Evaluating the Effectiveness of Ibuprofen Versus Acetaminophen in Closing Patent Ductus Arteriosus in Preterm Neonates.Children (Basel, Switzerland) · 2026Article
- Xanthomatous pleuritis in a child with recurrent pneumonia and patent ductus arteriosus: A rare pediatric case report and literature review.Respiratory medicine case reports · 2026Article
- Impact of the Time to Initiation of Indomethacin or Ibuprofen on Patent Ductus Arteriosus Closure Rates.Paediatric drugs · 2026Article
- Pre-procedural three-dimensional computed tomography vs. angiographic assessment for patent ductus arteriosus stenting: a comparative analysis.Frontiers in cardiovascular medicine · 2026Article
- Patent ductus arteriosus in Qatar: a retrospective study on epidemiology and neonatal outcomes following transcatheter closure.Frontiers in pediatrics · 2026Article
- Β3-Adrenergic Receptors and Prematurity-Related Diseases: A Systematic Review.Children (Basel, Switzerland) · 2025Review
- Paracetamol Concentrations and Time-Course of Ductus Arteriosus Diameter in Extremely Preterm Neonates: A Population Pharmacokinetic-Pharmacodynamic Analysis.Clinical pharmacokinetics · 2025Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patent ductus arteriosus (PDA) is one of the most common congenital heart defects, accounting for 5%-10% of all congenital heart disease in term infants. The occurrence of PDA is inversely related to gestational age and weight, with an even greater incidence in preterm infants. The maintenance of ductal patency is essential for the normal development of the fetus. In the neonate, however, persistent patency of the ductus arteriosus (DA) is associated with significant morbidity and mortality. Normally, at birth, the DA constricts, resulting in intraluminal ischemic hypoxia, which eventually leads to closure and remodeling of the ductus. PDA in term infants is usually associated with a functional defect, whereas in preterm infants it is associated with immaturity. Normal physiologic mechanisms contributing to closure - oxygen tension and decreased prostaglandins-are altered in prematurity. Clinical signs of ductal patency include murmur, tachycardia, bounding peripheral pulses, and congestive heart failure and associated symptoms. Symptoms are not always present; therefore, diagnostic imaging is critical if a PDA is suspected on clinical grounds. Three management strategies are currently available for PDA: fluid restriction and diuretics (as clinically appropriate), medical intervention, and surgical ligation. Pharmacologic closure can be achieved via administration of intravenous indomethacin or ibuprofen lysine. While both agents have shown similar efficacy, ibuprofen lysine has demonstrated an improved safety profile, particularly in terms of renal effects, compared to indomethacin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.